Yoshida et al. (2024) reported that patients treated with JAK or IL-6 inhibitors exhibited significantly higher infection rates than those receiving conventional DMARDs, particularly affecting the respiratory and central nervous systems [9]. The gene discussed is IL6; the disease is infection.